Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics Income Statement

Financials in millions USD. Fiscal year is December - November.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 30, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021	Nov 30, 2020
Revenue	54.55	76.99	38.63	29.75	17.82
Revenue Growth (YoY)	-29.14%	99.31%	29.84%	66.95%	-42.73%
Cost of Revenue	221.63	189.15	184.5	116.43	66.49
Gross Profit	-167.08	-112.16	-145.87	-86.68	-48.67
Selling, General & Admin	45.94	42.9	38	31.2	16.31
Operating Expenses	45.94	42.9	38	31.2	16.31
Operating Income	-213.03	-155.06	-183.87	-117.89	-64.98
Interest & Investment Income	19.73	11.12	3.51	0.82	1.21
Pretax Income	-193.3	-143.95	-180.36	-117.06	-63.78
Income Tax Expense	0.27	-	-	0.13	-20.54
Net Income	-193.57	-143.95	-180.36	-117.19	-43.24
Net Income to Common	-193.57	-143.95	-180.36	-117.19	-43.24
Shares Outstanding (Basic)	67	54	49	43	16
Shares Outstanding (Diluted)	67	54	49	43	16
Shares Change (YoY)	23.52%	11.79%	13.32%	173.68%	376.03%
EPS (Basic)	-2.88	-2.65	-3.71	-2.73	-2.76
EPS (Diluted)	-2.88	-2.65	-3.71	-2.73	-2.76
Free Cash Flow	-181.86	-89.77	-172.05	-90.03	-4.63
Free Cash Flow Per Share	-2.71	-1.65	-3.54	-2.10	-0.30
Gross Margin	-	-145.69%	-	-291.38%	-273.14%
Operating Margin	-390.52%	-201.41%	-476.01%	-396.25%	-364.66%
Profit Margin	-354.85%	-186.98%	-466.93%	-393.93%	-242.66%
Free Cash Flow Margin	-333.38%	-116.60%	-445.42%	-302.61%	-26.00%
EBITDA	-205.01	-148.93	-179.72	-115.9	-62.8
EBITDA Margin	-	-193.45%	-	-	-
D&A For EBITDA	8.02	6.13	4.15	1.99	2.18
EBIT	-213.03	-155.06	-183.87	-117.89	-64.98
EBIT Margin	-	-201.41%	-	-	-
Revenue as Reported	54.55	76.99	38.63	-	-

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q